Skip to content
Calculator
Compare

Peptide comparisons

Last updated: October 2, 2026 · 8 min read · By the Grey Peptides Editorial Board

A white parasol against a clear blue sky
Photo by Jan van der Wolf on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • Every table cell is read from the encyclopedia entry for that compound; nothing is scored or ranked.
  • Each analysis cites the trials it uses, and head-to-head trials are named where they exist.

Comparisons

  • Afamelanotide vs Melanotan II: Afamelanotide, once called melanotan I, is an approved implant for a rare light-sensitivity disease. Melanotan II, its cousin, is sold online as a tanning injection with almost no trial data. The names are similar; the evidence is not.
  • AHK-Cu vs GHK-Cu: AHK-Cu and GHK-Cu are near-identical copper tripeptides that differ by one amino acid. GHK-Cu occurs naturally in human blood and has a modest literature of cell, animal and a few small human studies; AHK-Cu, sold for hair growth, has one laboratory study of human hair follicles. Here is how they compare.
  • Amycretin vs CagriSema: Amycretin and CagriSema side by side: Novo Nordisk's two ways of combining GLP-1 and amylin, one molecule against two, the weight data for each, and why the numbers cannot simply be compared.
  • AOD-9604 vs semaglutide: AOD-9604 is a fragment of growth hormone that trimmed fat in obese rodents and was dropped in 2007 after its largest human trial found no significant weight loss. Semaglutide is an approved weight-loss drug that cut body weight by about 15% in a 68-week trial. They are often listed side by side online; the evidence puts them in different categories.
  • ARA-290 vs BPC-157: ARA-290 and BPC-157 are both sold for repair and pain. ARA-290 has small placebo-controlled human trials in nerve pain; BPC-157 has decades of rodent work and three small human studies.
  • Argireline vs SNAP-8: SNAP-8 is Argireline with two more amino acids, sold as a stronger version. Argireline has several small human trials; SNAP-8 has none of its own, only two multi-ingredient microneedle studies. The longer peptide also faces a harder trip through the skin.
  • BPC-157 vs GHK-Cu: BPC-157 and GHK-Cu are both sold as healing peptides and often blended together. BPC-157's evidence is rodent injury studies; GHK-Cu's human evidence is on skin, as a cream. Neither has a controlled human trial of injection.
  • Cagrilintide vs pramlintide: Cagrilintide and pramlintide side by side: two amylin analogs, one an approved but now discontinued mealtime diabetes injection and one a weekly obesity drug still in trials.
  • Cerebrolysin vs Semax: Cerebrolysin and semax are both used after strokes in parts of Europe and Asia and both are sold online as brain boosters. One is a pig-brain infusion with a Cochrane review; the other is a synthetic nasal drop with small Russian studies.
  • CJC-1295 vs sermorelin: CJC-1295 is sermorelin's peptide bonded to albumin so it lasts about a week. What that changes, what its two human studies found, and why the FDA flagged safety concerns.
  • Dihexa vs Semax: Dihexa and semax are both sold as compounds that grow brain connections. Semax has small human studies and a Russian approval; dihexa has no human studies, retracted mechanism papers and a cancer-linked target.
  • DSIP vs Epitalon: DSIP and epitalon are both sold for sleep and ageing. DSIP had small insomnia trials in the 1980s and 1990s with mixed results; epitalon's evidence is mostly cell and animal work from one St. Petersburg group.
  • Epitalon vs Thymalin: Epitalon and thymalin come from the same St. Petersburg research programme. Thymalin is a thymus extract approved in Russia; epitalon is a synthetic peptide with mainly cell and animal data. Neither has strong independent human evidence.
  • Exenatide vs liraglutide: Exenatide and liraglutide side by side: the first two GLP-1 drugs, their head-to-head trial, outcome trials, weight results and where each stands today.
  • GHK-Cu vs Matrixyl: Both are sold as collagen-boosting peptides for skin. Matrixyl has a 93-woman randomised split-face trial behind it; GHK-Cu has decades of cell and animal work and almost no controlled human skin trials. Here is what each has actually shown.
  • GHRP-2 vs GHRP-6: GHRP-2 and GHRP-6 are the two best-studied growth hormone-releasing peptides. One became a diagnostic test in Japan; the other never left the laboratory. What their human studies show.
  • hCG vs gonadorelin: hCG acts directly on the gonads, imitating LH. Gonadorelin acts on the pituitary, and only works if delivered in pulses. One is approved and widely used; the other's human products were discontinued. They are not interchangeable, and the half-lives explain why.
  • Hexarelin vs Ipamorelin: Hexarelin and ipamorelin are both ghrelin-receptor peptides that release growth hormone. Hexarelin has the bigger human record, including a 16-week study showing the response fades; ipamorelin has one dosing study and one failed trial.
  • Humanin vs MOTS-c: Humanin and MOTS-c are both peptides encoded in mitochondrial DNA, and both are sold for longevity and metabolism. Neither has ever been given to people in a published treatment trial; their evidence is cells, animals and blood measurements.
  • IGF-1 LR3 vs MGF: IGF-1 LR3 and MGF are both sold for muscle growth and both come from IGF-1, but they are very different molecules. Neither has ever been given to a person in a published study.
  • Ipamorelin vs GHRP-6: Ipamorelin came after GHRP-6 and proved more selective in animal tests. What 'selective' meant in the studies, what each has been tested for in people, and where each stands.
  • Ipamorelin vs sermorelin: Ipamorelin and sermorelin side by side: one copies the hormone that tells the pituitary to release growth hormone, the other mimics ghrelin; what each has been tested for, and where each stands.
  • Kisspeptin vs Gonadorelin: Gonadorelin is synthetic GnRH, the hormone that tells the pituitary to release LH and FSH; kisspeptin sits one step higher, telling the brain to release GnRH. Gonadorelin had FDA approvals now discontinued; kisspeptin is still investigational, with notable IVF trials.
  • KPV vs BPC-157: KPV and BPC-157 are both marketed for gut inflammation and both passed FDA's compounding committee vote in July 2026. KPV has never been tested in people; BPC-157's human record is a few small studies; its only gut study, a randomised colitis trial, exists only as a 2005 meeting abstract FDA judged inadequate.
  • LL-37 vs thymosin alpha-1: LL-37 and thymosin alpha-1 are both sold as immune peptides. Thymosin alpha-1 is an approved drug in about 35 countries, with randomised trials including a large negative sepsis trial. LL-37 has been tested mainly on the skin of chronic ulcers, where its main trial missed its goal.
  • Matrixyl vs Argireline: These two peptides attack wrinkles from opposite directions: Matrixyl is meant to rebuild collagen under fine lines, Argireline to quiet the muscles that crease expression lines. One small randomised trial has compared them directly, and Matrixyl came out ahead.
  • MK-677 vs Ipamorelin: MK-677 and ipamorelin both release growth hormone through the ghrelin receptor, but MK-677 is an oral small molecule tested in year-long trials, and ipamorelin is an injected peptide with one dosing study and one failed trial.
  • MOTS-c vs SS-31: MOTS-c and SS-31 are both called mitochondrial peptides, but they are very different. SS-31 (elamipretide) has phase 3 trials and an FDA accelerated approval for Barth syndrome; MOTS-c has animal data and no treatment trials in people.
  • Noopept vs Semax: Noopept and semax are both approved in Russia and sold elsewhere as nootropics. One is an oral dipeptide-derived drug; the other is a nasal ACTH fragment. Their human evidence is small, Russian, and open or not described as blinded.
  • Orforglipron vs oral semaglutide: Orforglipron and oral semaglutide side by side: a small-molecule GLP-1 pill against a peptide tablet, and the ACHIEVE-3 trial that compared them directly.
  • PT-141 vs Melanotan II: PT-141 and melanotan II are close relatives in the melanocortin family. PT-141 became Vyleesi, an approved drug for low sexual desire in premenopausal women; melanotan II never got past tiny studies and is sold online for tanning.
  • Semaglutide vs dulaglutide: Semaglutide and dulaglutide side by side: two weekly GLP-1 drugs, their one head-to-head trial, their heart and kidney outcome trials, doses and status.
  • Semaglutide vs liraglutide: Semaglutide and liraglutide side by side: the head-to-head trials for weight and diabetes, the heart-outcome trials, and why one is weekly and the other daily.
  • Semax vs Selank: Semax and selank are two Russian nasal peptides discussed as nootropics. One is a stroke and nerve drug in Russia, the other an anti-anxiety drug. What their human studies actually show.
  • Somatropin vs sermorelin: Somatropin is growth hormone itself, approved for a long list of conditions with decades of trials. Sermorelin is a fragment of the hormone that tells the pituitary to release it, once approved as a diagnostic and growth treatment for children and since discontinued. They are not interchangeable.
  • Survodutide vs mazdutide: Survodutide and mazdutide side by side: two drugs that act on both the GLP-1 and glucagon receptors, their trial results, and where each stands on approval.
  • Tesamorelin vs CJC-1295: Tesamorelin and CJC-1295 both mimic GHRH, the hormone that tells the pituitary to release growth hormone. Tesamorelin is FDA-approved after trials in more than 800 people; CJC-1295 was tested in two small studies and never approved.
  • Tesamorelin vs sermorelin: Tesamorelin and sermorelin both copy growth hormone-releasing hormone. One is an approved drug with modern phase 3 trials; the other is a discontinued product with an older, narrower record.
  • Thymosin alpha-1 vs thymulin: Thymosin alpha-1 and thymulin both come from the thymus, the organ that trains immune T cells, and both are sold as immune peptides. Thymosin alpha-1 is an approved drug in about 35 countries with randomised trials, including a large negative one in sepsis. Thymulin has been measured in people far more often than given to them. Here is how they compare.
  • Triptorelin vs leuprolide: Triptorelin and leuprolide are GnRH agonists, synthetic versions of the brain's reproductive hormone that switch off sex-hormone production when given continuously. Both are approved drugs used in prostate cancer, early puberty and gynaecology. Here is how they compare in the head-to-head trial, in children, and in their formulations.

Frequently asked questions

How are these comparisons built?

The table is drawn from our dataset, the same fields the encyclopedia entries print, and the analysis below it cites each trial it relies on.

Sources

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All comparisons

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead